

Michael R Zile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/993633/publications.pdf>

Version: 2024-02-01

358
papers

41,823
citations

2671

95
h-index

2680

193
g-index

364
all docs

364
docs citations

364
times ranked

24276
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF. PLoS ONE, 2022, 17, e0262479.	1.1	1
2	Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from <scp>PARAGON-HF</scp>. European Journal of Heart Failure, 2022, 24, 672-677.	2.9	6
3	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in <scp>PARADIGM-HF</scp>. European Journal of Heart Failure, 2022, 24, 551-561.	2.9	20
4	Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509.	2.9	30
5	Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes. Nature Communications, 2022, 13, 203.	5.8	71
6	<scp>Angiotensin-neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598.	2.9	14
7	Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure. Journal of the American Heart Association, 2022, 11, e024095.	1.6	10
8	The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. European Heart Journal, 2022, 43, 2603-2618.	1.0	27
9	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 336-346.	1.9	18
10	Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC: Heart Failure, 2022, 10, 415-427.	1.9	4
11	Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H798-H805.	1.5	4
12	Mechanisms that limit regression of myocardial fibrosis following removal of left ventricular pressure overload. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H165-H175.	1.5	5
13	Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology, 2022, 21, .	2.7	14
14	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. American Journal of Medicine, 2021, 134, e252-e263.	0.6	14
15	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clinical Research in Cardiology, 2021, 110, 1234-1248.	1.5	8
16	The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice. Human Molecular Genetics, 2021, 29, 3504-3515.	1.4	9
17	Pathophysiology of Heart Failure With a Preserved Ejection Fraction: Measurements and Mechanisms Causing Abnormal Diastolic Function. , 2021, , 11-30.		0
18	Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Failure, 2021, 8, 1706-1710.	1.4	23

#	ARTICLE	IF	CITATIONS
19	Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. ESC Heart Failure, 2021, 8, 1130-1138.	1.4	21
20	INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 849-860.	1.4	3
21	SPARC production by bone marrow-derived cells contributes to myocardial fibrosis in pressure overload. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H604-H612.	1.5	15
22	Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?. Heart Rhythm O2, 2021, 2, 37-45.	0.6	5
23	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. Journal of the American Heart Association, 2021, 10, e019238.	1.6	20
24	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 2021, 23, 776-784.	2.9	12
25	Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. Journal of the American Heart Association, 2021, 10, e018127.	1.6	7
26	Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovascular Disorders, 2021, 21, 155.	0.7	7
27	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	1.6	13
28	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	2.9	11
29	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. Journal of the American College of Cardiology, 2021, 77, 1961-1973.	1.2	35
30	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	1.6	25
31	The Vexing Problem of HFpEF Therapeutics. JACC: Heart Failure, 2021, 9, 371-373.	1.9	1
32	From Systemic Inflammation to Myocardial Fibrosis. Circulation Research, 2021, 128, 1451-1467.	2.0	132
33	Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion. American Journal of Medicine, 2021, 134, 797-804.	0.6	6
34	Influence of Study Discontinuation during the Run-in Period on the Estimated Efficacy of Sacubitril/valsartan in the PARAGON-HF Trial. European Journal of Heart Failure, 2021, , .	2.9	5
35	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. European Journal of Heart Failure, 2021, 23, 1518-1524.	2.9	20
36	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFpEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 2021, 110, 1334-1349.	1.5	4

#	ARTICLE	IF	CITATIONS
37	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.	1.2	3
38	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
39	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019545.	1.6	29
40	Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. <i>Lancet</i> , 2021, 398, 991-1001.	6.3	218
41	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. <i>Journal of Cardiac Failure</i> , 2021, 27, 1027-1030.	0.7	0
42	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in AHFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	1.9	21
43	A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone. <i>Circulation</i> , 2021, 144, 1269-1271.	1.6	8
44	Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e022930.	1.6	10
45	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13
46	Should We Test for Diastolic Dysfunction? How and How Often?. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 297-309.	2.3	11
47	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
48	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
49	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 528-538.	2.9	28
50	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. <i>JACC: Heart Failure</i> , 2020, 8, 844-855.	1.9	56
51	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020, 7, 3355-3364.	1.4	9
52	Effect of Pralicyguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1522.	3.8	79
53	Prediction of worsening heart failure events and all-cause mortality using an individualized risk stratification strategy. <i>ESC Heart Failure</i> , 2020, 7, 4277-4289.	1.4	14
54	Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 669-679.	1.2	41

#	ARTICLE	IF	CITATIONS
55	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020, 22, 2370-2379.	2.9	14
56	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020, 76, 503-514.	1.2	77
57	Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance. <i>ESC Heart Failure</i> , 2020, 7, 3040-3048.	1.4	3
58	Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. <i>Clinical Cardiology</i> , 2020, 43, 1501-1510.	0.7	5
59	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 2093-2101.	2.9	33
60	Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2056-2064.	2.9	34
61	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2417-2418.	1.2	0
62	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1662-1671.	2.9	33
63	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	1.9	17
64	Changes in Myocardial Microstructure and Mechanics With Progressive Left Ventricular Pressure Overload. <i>JACC Basic To Translational Science</i> , 2020, 5, 463-480.	1.9	9
65	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. <i>JACC: Heart Failure</i> , 2020, 8, 347-358.	1.9	53
66	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1358-1365.	1.5	11
67	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 372-381.	1.9	53
68	Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1-13.	1.2	121
69	Pressure overload generates a cardiac-specific profile of inflammatory mediators. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 319, H331-H340.	1.5	13
70	Angiotensin Receptor-Nephrilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. <i>Circulation: Heart Failure</i> , 2020, 13, e006696.	1.6	22
71	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006541.	1.6	96
72	Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). <i>American Heart Journal</i> , 2020, 222, 183-190.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	3.0	59
74	The prevalence and importance of frailty in heart failure with reduced ejection fraction—An analysis of <scp>PARADIGMâ€HF</scp> and <scp>ATMOSPHERE</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 2123-2133.	2.9	85
75	Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>American Journal of Medicine</i> , 2020, 133, 1187-1194.	0.6	9
76	Reply. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1501-1502.	1.2	0
77	Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. <i>Journal of Cardiac Failure</i> , 2020, 26, 876-884.	0.7	4
78	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019, 21, 23-36.	2.9	102
79	Safety and Feasibility of a Nocturnal Heart Rate Elevation—Exploration of a Novel Treatment Concept. <i>Journal of Cardiac Failure</i> , 2019, 25, 67-71.	0.7	9
80	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013114.	1.6	69
81	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	1.9	77
82	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	1.2	97
83	Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. <i>American Journal of Cardiology</i> , 2019, 124, 756-762.	0.7	16
84	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	2.9	52
85	Angiotensin—Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
86	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1369-1379.	1.6	74
87	Repetitive Acute Hemodynamic Load. <i>JACC Basic To Translational Science</i> , 2019, 4, 542-545.	1.9	0
88	Outcomes and Effect of Treatment According to Etiology in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 457-465.	1.9	94
89	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 418-427.	1.9	20
90	Mitochondrial biogenesis induced by the β -adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. <i>Kidney International</i> , 2019, 96, 656-673.	2.6	44

#	ARTICLE	IF	CITATIONS
91	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). American Heart Journal, 2019, 214, 18-27.	1.2	41
92	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. Journal of the American College of Cardiology, 2019, 73, 1264-1272.	1.2	139
93	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circulation: Heart Failure, 2019, 12, e005766.	1.6	21
94	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFREF. Journal of the American College of Cardiology, 2019, 73, 795-806.	1.2	173
95	Income Inequality and Outcomes in Heart Failure. JACC: Heart Failure, 2019, 7, 336-346.	1.9	63
96	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. European Journal of Heart Failure, 2019, 21, 337-341.	2.9	129
97	Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2019, 4, 924-937.	1.9	24
98	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 2858-2873.	1.2	138
99	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006539.	1.6	78
100	Elevated Wall Tension Leads to Reduced miR-133a in the Thoracic Aorta by Exosome Release. Journal of the American Heart Association, 2019, 8, e010332.	1.6	15
101	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. Journal of the American College of Cardiology, 2019, 73, 29-40.	1.2	168
102	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 2019, 21, 577-587.	2.9	38
103	The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49.	2.9	54
104	Changes in the crystallographic structures of cardiac myosin filaments detected by polarization-dependent second harmonic generation microscopy. Biomedical Optics Express, 2019, 10, 3183.	1.5	8
105	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 2018, 6, 547-554.	5.5	124
106	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. JAMA Cardiology, 2018, 3, 498.	3.0	84
107	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498.	1.9	272
108	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. Circulation: Heart Failure, 2018, 11, e004745.	1.6	55

#	ARTICLE	IF	CITATIONS
109	Cardiac macrophages promote diastolic dysfunction. <i>Journal of Experimental Medicine</i> , 2018, 215, 423-440.	4.2	314
110	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018, 20, 760-768.	2.9	62
111	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 2018, 266, 187-192.	0.8	27
112	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 564-569.	1.9	43
113	Attenuation of accelerated renal cystogenesis in <i>Pkd1</i> mice by renin-angiotensin system blockade. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F210-F218.	1.3	16
114	Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 1232.	3.0	12
115	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nepriylsin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1226.	3.0	38
116	Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy <i>Comment on:</i> "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi <i>et al.</i>. <i>ESC Heart Failure</i> , 2018, 5, 1069-1071.	1.4	15
117	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018, 138, 2763-2773.	1.6	52
118	Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , 2018, 24, 682-694.	0.7	70
119	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Nepriylsin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.	1.6	40
120	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1701-1709.	2.9	56
121	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. <i>American Journal of Medicine</i> , 2018, 131, 1473-1481.	0.6	26
122	Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H92-H100.	1.5	43
123	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. <i>American Heart Journal</i> , 2018, 205, 1-11.	1.2	84
124	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
125	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to) <i>Tj ETQq1 1 0,784314 rgBT /Over</i> 11, e004446.	1.6	58
126	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. <i>American Heart Journal</i> , 2018, 204, 139-150.	1.2	27

#	ARTICLE	IF	CITATIONS
127	Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H958-H967.	1.5	32
128	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018, 15, e1002541.	3.9	97
129	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.	1.0	36
130	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	79
131	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 135, e1054-e1091.	1.6	417
132	Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course. <i>Journal of Palliative Medicine</i> , 2017, 20, 1068-1073.	0.6	9
133	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , 2017, 38, 1132-1143.	1.0	160
134	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017, 188, 35-41.	1.2	32
135	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 333-340.	5.5	258
136	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2017, 135, 724-735.	1.6	153
137	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1861-1871.	1.2	34
138	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53
139	Health-Related Quality of Life Outcomes in PARADIGM-HF. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	150
140	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53
141	Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. <i>Physiological Reports</i> , 2017, 5, e13462.	0.7	8
142	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.	1.2	114
143	Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates. <i>Heart and Vessels</i> , 2017, 32, 1202-1213.	0.5	11
144	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 471-482.	1.9	238

#	ARTICLE	IF	CITATIONS
145	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017, 377, 41-51.	13.9	355
146	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. <i>JAMA Cardiology</i> , 2017, 2, 79.	3.0	143
147	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.	0.7	35
148	Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 291-298.	1.3	30
149	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 129-137.	2.9	95
150	Activation of Inflammatory and Pro-Thrombotic Pathways in Acute Stress Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 49.	1.1	18
151	Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E1027-E1035.	1.8	40
152	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	1.0	114
153	Efficacy of Sacubitril/Valsartan Relative to Prior Decompensation. <i>JACC: Heart Failure</i> , 2016, 4, 816-822.	1.9	84
154	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	2.9	17
155	Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 753-760.	0.7	141
156	Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2690-2707.	1.2	83
157	The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio. <i>International Journal of Cardiology</i> , 2016, 215, 521-526.	0.8	17
158	Lactosylceramide contributes to mitochondrial dysfunction in diabetes. <i>Journal of Lipid Research</i> , 2016, 57, 546-562.	2.0	41
159	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002763.	1.6	224
160	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. <i>Circulation</i> , 2016, 133, 2254-2262.	1.6	142
161	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 320-328.	0.4	26
162	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1228-1234.	2.9	173

#	ARTICLE	IF	CITATIONS
163	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2425-2436.	1.2	271
164	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2016, 134, 1785-1787.	1.6	35
165	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Tj ETQq1 1 0.784314 rgBT /Ov Therapy. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	83
166	Could Modification of Titin Contribute to an Answer for Heart Failure With Preserved Ejection Fraction?. <i>Circulation</i> , 2016, 134, 1100-1104.	1.6	8
167	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , 2016, 68, 241-248.	1.2	101
168	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	46
169	Cardiosphere-Derived Cells Reverse Heart Failure With Preserved Ejection Fraction in Rats by Decreasing Fibrosis and Inflammation. <i>JACC Basic To Translational Science</i> , 2016, 1, 14-28.	1.9	95
170	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	52
171	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 666.	3.0	130
172	Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2016, 134, 73-90.	1.6	747
173	Risk Related to Prevalent Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	260
174	Is Biventricular Fibrosis the Mediator of Late Complications in Tetralogy of Fallot?. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 11-13.	2.3	10
175	Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. <i>FASEB Journal</i> , 2016, 30, 370-379.	0.2	27
176	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	93
177	Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. <i>Circulation: Heart Failure</i> , 2016, 9, e002543.	1.6	18
178	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002744.	1.6	130
179	Influenza Vaccination in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 152-158.	1.9	112
180	How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF) Tj ETQq0 0 0 rgBT /Ovlock 10 Tf 00		

#	ARTICLE	IF	CITATIONS
181	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the PReserve study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	2.9	52
182	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015, 17, 925-935.	2.9	203
183	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015, 36, 1990-1997.	1.0	335
184	Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates. <i>Hypertension Research</i> , 2015, 38, 551-559.	1.5	18
185	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015, 17, 1066-1074.	2.9	85
186	Estimating the Long-Term Treatment Benefits of Sacubitril/Valsartan. <i>New England Journal of Medicine</i> , 2015, 373, 2289-2290.	13.9	92
187	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
188	A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study. <i>Journal of Cardiology</i> , 2015, 66, 253-262.	0.8	16
189	Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2015, 131, 1247-1259.	1.6	509
190	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015, 36, 434-439.	1.0	80
191	Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 510-517.	2.9	153
192	Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals. <i>Circulation: Heart Failure</i> , 2015, 8, 17-24.	1.6	11
193	Response to Letters Regarding Article, "Systolic and Diastolic Mechanics in Stress Cardiomyopathy". <i>Circulation</i> , 2015, 131, e372.	1.6	1
194	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 169-176.	2.9	36
195	Estrogen-Related Receptor β (ERR β) is required for adaptive increases in PGC-1 isoform expression during electrically stimulated contraction of adult cardiomyocytes in sustained hypoxic conditions. <i>International Journal of Cardiology</i> , 2015, 187, 393-400.	0.8	12
196	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 429-441.	1.9	72
197	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 487-496.	1.9	204
198	Dual-Source CT Imaging to Plan Transcatheter Aortic Valve Replacement: Accuracy for Diagnosis of Obstructive Coronary Artery Disease. <i>Radiology</i> , 2015, 275, 80-88.	3.6	62

#	ARTICLE	IF	CITATIONS
199	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.	1.2	118
200	Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 308, C972-C982.	2.1	46
201	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. <i>Circulation: Heart Failure</i> , 2015, 8, 717-724.	1.6	22
202	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015, 36, 2576-2584.	1.0	187
203	Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F79-F87.	1.3	16
204	Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 733-740.	1.6	30
205	HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis. <i>Circulation: Heart Failure</i> , 2015, 8, 1094-1104.	1.6	53
206	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 478-486.	1.9	21
207	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
208	Abstract 17955: Reduction in 30-day Rehospitalization After Discharge From a Heart Failure Admission in Patients Receiving LCZ696 versus Enalapril: PARADIGM-HF. <i>Circulation</i> , 2015, 132, .	1.6	0
209	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014, 7, 953-959.	1.6	80
210	Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H752-H761.	1.5	12
211	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78
212	Age and SPARC Change the Extracellular Matrix Composition of the Left Ventricle. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	39
213	History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 960-966.	1.6	35
214	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1096-1103.	2.9	194
215	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 535-542.	2.9	184
216	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	1.6	218

#	ARTICLE	IF	CITATIONS
217	Renal Sympathetic Denervation for Blood Pressure Control: A Review of the Current Evidence and Ongoing Studies. <i>Journal of Clinical Hypertension</i> , 2014, 16, 331-341.	1.0	7
218	Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 447-456.	1.2	591
219	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
220	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <sc>LCZ696</sc>, in patients with heart failure with preserved ejection fraction: an analysis of the <sc>PARAMOUNT</sc> trial. <i>European Journal of Heart Failure</i> , 2014, 16, 671-677.	2.9	67
221	Mechanistic Relationship Between Membrane Type-1 Matrix Metalloproteinase and the Myocardial Response to Pressure Overload. <i>Circulation: Heart Failure</i> , 2014, 7, 340-350.	1.6	19
222	Baseline characteristics and treatment of patients in Prospective comparison of <sc>ARNI</sc> with <sc>ACEI</sc> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<sc>PARADIGM-HF</sc>). <i>European Journal of Heart Failure</i> , 2014, 16, 817-825.	2.9	148
223	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1175-1182.	2.9	64
224	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , 2014, 16, 778-787.	2.9	80
225	Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1106-1113.	1.2	67
226	The Natural History of Left Ventricular Geometry in the Community. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 870-878.	2.3	134
227	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.	1.0	61
228	Lack of Association Between Spironolactone Use and 30-Day All-Cause Readmission In Hospitalized Medicare Beneficiaries With Systolic Heart Failure Eligible for Spironolactone Therapy. <i>Journal of Cardiac Failure</i> , 2014, 20, S58.	0.7	1
229	Angiotensinâ€“Neprilysin Inhibition versus Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 993-1004.	13.9	5,052
230	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1535-1536.	1.2	0
231	Systolic and Diastolic Mechanics in Stress Cardiomyopathy. <i>Circulation</i> , 2014, 129, 1659-1667.	1.6	93
232	Myocardial fibroblastâ€“matrix interactions and potential therapeutic targets. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 70, 92-99.	0.9	76
233	Adverse Left Ventricular Remodeling in Community-Dwelling Older Adults Predicts Incident Heart Failure and Mortality. <i>JACC: Heart Failure</i> , 2014, 2, 512-522.	1.9	67
234	Randomized, Double-Blind, Placebo-Controlled Study of Sitaxsentan to Improve Impaired Exercise Tolerance in Patients With Heart Failure and a Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 123-130.	1.9	70

#	ARTICLE	IF	CITATIONS
235	Digoxin and 30-day All-cause Hospital Admission in Older Patients with Chronic Diastolic Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 132-139.	0.6	19
236	Abstract 15308: SPARC Deletion Suppresses Age-related Cardiac Inflammation. <i>Circulation</i> , 2014, 130, .	1.6	0
237	Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis: Application to Heart Failure with a Preserved Ejection Fraction. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 501-515.	1.1	64
238	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€CHF). <i>European Journal of Heart Failure</i> , 2013, 15, 1062-1073.	2.9	358
239	Renin-Angiotensin Inhibition in Diastolic Heart Failure and Chronic Kidney Disease. <i>American Journal of Medicine</i> , 2013, 126, 150-161.	0.6	29
240	Membrane-Associated Matrix Proteolysis and Heart Failure. <i>Circulation Research</i> , 2013, 112, 195-208.	2.0	140
241	Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. <i>European Heart Journal</i> , 2013, 34, 676-683.	1.0	59
242	Integrating the Myocardial Matrix Into Heart Failure Recognition and Management. <i>Circulation Research</i> , 2013, 113, 725-738.	2.0	67
243	Relation of N-Terminal Pro-B-Type Natriuretic Peptide With Diastolic Function in Hypertensive Heart Disease. <i>American Journal of Hypertension</i> , 2013, 26, 1234-1241.	1.0	17
244	Effects of Exercise on Left Ventricular Systolic and Diastolic Properties in Patients With Heart Failure and a Preserved Ejection Fraction Versus Heart Failure and a Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2013, 6, 508-516.	1.6	50
245	Neuromodulation Device Therapy for Treatment of Hypertensive Heart Disease. <i>Circulation Journal</i> , 2013, 77, 1351-1363.	0.7	5
246	Response to Letters Regarding Article, â€œPrevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fractionâ€. <i>Circulation</i> , 2012, 126, .	1.6	0
247	Myosin Cross-Bridge Dynamics in Patients With Hypertension and Concentric Left Ventricular Remodeling. <i>Circulation: Heart Failure</i> , 2012, 5, 803-811.	1.6	36
248	Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 571-578.	1.6	177
249	Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1429-H1437.	1.5	39
250	Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H1128-H1134.	1.5	35
251	HFpEF: Cardiovascular Abnormalities Not Just Comorbidities. <i>Circulation: Heart Failure</i> , 2012, 5, 669-671.	1.6	32
252	Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 303, H234-H240.	1.5	46

#	ARTICLE	IF	CITATIONS
253	Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 217-225.	1.6	63
254	Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. <i>Journal of Clinical Investigation</i> , 2012, 122, 3919-3930.	3.9	175
255	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet</i> , 2012, 380, 1387-1395.	6.3	990
256	The Heart Failure Society of America in 2020: A Vision for the Future. <i>Journal of Cardiac Failure</i> , 2012, 18, 90-93.	0.7	3
257	Changes in Plasma Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of MMPs in Stress-Induced Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2012, 18, 487-492.	0.7	22
258	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. <i>Drug Safety</i> , 2012, 35, 233-244.	1.4	40
259	Effects of Autonomic Modulation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 910-912.	1.2	17
260	In-Hospital Resource Use and Medical Costs in the Last Year of Life by Mode of Death (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	0.7	28
261	β 3 Integrin in Cardiac Fibroblasts Critical for Extracellular Matrix Accumulation during Pressure Overload Hypertrophy in Mouse. <i>PLoS ONE</i> , 2012, 7, e45076.	1.1	50
262	In vivo measurements of the contributions of protein synthesis and protein degradation in regulating cardiac pressure overload hypertrophy in the mouse. <i>Molecular and Cellular Biochemistry</i> , 2012, 367, 205-213.	1.4	6
263	Myocardial remodeling with aortic stenosis and after aortic valve replacement: Mechanisms and future prognostic implications. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 656-664.	0.4	88
264	Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 215-223.	0.4	54
265	Relationship Between the Temporal Profile of Plasma microRNA and Left Ventricular Remodeling in Patients After Myocardial Infarction. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 614-619.	5.1	131
266	Plasma Biomarkers That Reflect Determinants of Matrix Composition Identify the Presence of Left Ventricular Hypertrophy and Diastolic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 246-256.	1.6	183
267	Left Ventricular Structural Remodeling in Health and Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1733-1740.	1.2	331
268	Chronic Baroreflex Activation: A Potential Therapeutic Approach to Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2011, 17, 167-178.	0.7	81
269	Hemodynamic Factors Associated With Acute Decompensated Heart Failure: Part 1—Insights into Pathophysiology. <i>Journal of Cardiac Failure</i> , 2011, 17, 282-291.	0.7	48
270	Hemodynamic Factors Associated With Acute Decompensated Heart Failure: Part 2—Use in Automated Detection. <i>Journal of Cardiac Failure</i> , 2011, 17, 366-373.	0.7	25

#	ARTICLE	IF	CITATIONS
271	Alterations in Ventricular Function. , 2011, , 213-231.		2
272	The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. <i>Journal of Hypertension</i> , 2011, 29, 1829-1836.	0.3	23
273	Continuous Hemodynamic Monitoring in Patients With Mild to Moderate Heart Failure: Results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) Trial. <i>Congestive Heart Failure</i> , 2011, 17, 248-254.	2.0	79
274	Natural History of Concentric Left Ventricular Geometry in Community-Dwelling Older Adults Without Heart Failure During Seven Years of Follow-Up. <i>American Journal of Cardiology</i> , 2011, 107, 321-324.	0.7	33
275	Left Ventricular Diastolic Function and Exercise Capacity in Community-Dwelling Adults ≥65 Years of Age Without Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 735-740.	0.7	12
276	Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 27-35.	1.6	216
277	Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 561-568.	1.6	91
278	Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 324-331.	1.6	238
279	Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 569-577.	1.6	219
280	Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2011, 124, 2491-2501.	1.6	418
281	Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H1696-H1706.	1.5	33
282	Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. <i>Histochemistry and Cell Biology</i> , 2010, 134, 23-30.	0.8	27
283	Chronic Ambulatory Intracardiac Pressures and Future Heart Failure Events. <i>Circulation: Heart Failure</i> , 2010, 3, 580-587.	1.6	120
284	Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2010, 121, 1393-1405.	1.6	290
285	Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H614-H622.	1.5	110
286	Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 86-92.	0.3	3
287	Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. <i>Journal of Cardiac Failure</i> , 2010, 16, 128-134.	0.7	53
288	Pressure Overload-Induced Alterations in Fibrillar Collagen Content and Myocardial Diastolic Function. <i>Circulation</i> , 2009, 119, 269-280.	1.6	127

#	ARTICLE	IF	CITATIONS
289	Integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. <i>FASEB Journal</i> , 2009, 23, 2759-2771.	0.2	53
290	Distribution of Left Ventricular Ejection Fraction in Patients With Ischemic and Hypertensive Heart Disease and Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2009, 104, 1413-1415.	0.7	25
291	Cardiopulmonary Exercise Variables in Diastolic Versus Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 203-206.	0.7	42
292	Patterns of Structural and Functional Remodeling of the Left Ventricle in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 459-462.	0.7	54
293	Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1073-1079.	1.2	483
294	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2008, 359, 2456-2467.	13.9	1,663
295	Application of Implantable Hemodynamic Monitoring in the Management of Patients With Diastolic Heart Failure: A Subgroup Analysis of the COMPASS-HF Trial. <i>Journal of Cardiac Failure</i> , 2008, 14, 816-823.	0.7	51
296	Pathophysiology of Diastolic Heart Failure: Relaxation and Stiffness. , 2008, , 11-25.		4
297	Effects of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure Inadequately Responsive to Medical Therapy. <i>Circulation</i> , 2008, 118, 1241-1249.	1.6	32
298	Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-156.	2.9	183
299	A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H2231-H2241.	1.5	27
300	In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H314-H326.	1.5	48
301	Transition From Chronic Compensated to Acute Decompensated Heart Failure. <i>Circulation</i> , 2008, 118, 1433-1441.	1.6	475
302	STAT3 Activation in Pressure-Overloaded Feline Myocardium: Role for Integrins and the Tyrosine Kinase BMX. <i>International Journal of Biological Sciences</i> , 2008, 4, 184-199.	2.6	30
303	Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. <i>Lancet</i> , The, 2007, 369, 2079-2087.	6.3	308
304	Effects of Age on Plasma Matrix Metalloproteinases (MMPs) and Tissue Inhibitor of Metalloproteinases (TIMPs). <i>Journal of Cardiac Failure</i> , 2007, 13, 530-540.	0.7	142
305	Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: A Propensity Matched Study—The Digitalis Investigation Group study was conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the Digitalis Investigation Group Investigators. This manuscript was prepared using a limited access data set obtained by the National Heart, Lung, and Blood Institute and does not necessarily reflect the opinions or views of the Digitalis Investigation Group. <i>American Journal of Cardiology</i> , 2007, 99, 393-398.	0.7	217
306	Hospitalizations Due to Unstable Angina Pectoris in Diastolic and Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2007, 99, 460-464.	0.7	26

#	ARTICLE	IF	CITATIONS
307	Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases. <i>Circulation</i> , 2006, 113, 2089-2096.	1.6	363
308	Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension. <i>American Heart Journal</i> , 2006, 152, 246-252.	1.2	22
309	Chronic Heart Failure: A Report From the Dartmouth Diastole Discourses. <i>Congestive Heart Failure</i> , 2006, 12, 162-165.	2.0	21
310	Contractile Behavior of the Left Ventricle in Diastolic Heart Failure. <i>Circulation</i> , 2006, 113, 296-304.	1.6	232
311	Response to Letter Regarding Article "Contractile Behavior of the Left Ventricle in Diastolic Heart Failure: With Emphasis on Regional Systolic Function". <i>Circulation</i> , 2006, 114, .	1.6	1
312	New Molecular Mechanism in Diastolic Heart Failure. <i>Circulation</i> , 2006, 113, 1922-1925.	1.6	82
313	Specific Temporal Profile of Matrix Metalloproteinase Release Occurs in Patients After Myocardial Infarction. <i>Circulation</i> , 2006, 114, 1020-1027.	1.6	176
314	Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure. <i>Circulation</i> , 2006, 114, 397-403.	1.6	539
315	Diastolic Heart Failure: Definitions and Terminology. <i>Progress in Cardiovascular Diseases</i> , 2005, 47, 307-313.	1.6	63
316	Continuous Aortic Flow Augmentation. <i>Circulation</i> , 2005, 112, 3107-3114.	1.6	33
317	Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H149-H158.	1.5	119
318	Left Ventricular Systolic Performance, Function, and Contractility in Patients With Diastolic Heart Failure. <i>Circulation</i> , 2005, 111, 2306-2312.	1.6	255
319	Treating Diastolic Heart Failure With Statins. <i>Circulation</i> , 2005, 112, 300-303.	1.6	24
320	The Effect of Alagebrium Chloride (ALT-711), a Novel Glucose Cross-Link Breaker, in the Treatment of Elderly Patients With Diastolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2005, 11, 191-195.	0.7	278
321	Plasma Monitoring of the Myocardial Specific Tissue Inhibitor of Metalloproteinase-4 After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2005, 11, 124-130.	0.7	16
322	The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design. <i>Journal of Cardiac Failure</i> , 2005, 11, 576-585.	0.7	129
323	A Finite Element Model for Drop-on-Demand Printing of Designer Hybrid Cardiovascular Constructs. , 2005, , .		0
324	Diastolic Heart Failure "Abnormalities in Active Relaxation and Passive Stiffness of the Left Ventricle. <i>New England Journal of Medicine</i> , 2004, 350, 1953-1959.	13.9	1,319

#	ARTICLE	IF	CITATIONS
325	Left Ventricular Diastolic Dysfunction and Diastolic Heart Failure. Annual Review of Medicine, 2004, 55, 373-394.	5.0	256
326	A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1) Tj ETQq0017 rgBT 125	0.7	0
327	Lack of relationship between doppler indices of diastolic function and left ventricular pressure transients in patients with definite diastolic heart failure. American Heart Journal, 2004, 148, 530.	1.2	37
328	Selective Matrix Metalloproteinase Inhibition With Developing Heart Failure. Circulation Research, 2003, 92, 177-185.	2.0	96
329	Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition. Circulation, 2003, 107, 618-625.	1.6	212
330	Heart Failure in Aortic Stenosis â€” Improving Diagnosis and Treatment. New England Journal of Medicine, 2003, 348, 1735-1736.	13.9	37
331	Changes in extracellular collagen matrix alter myocardial systolic performance. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H122-H132.	1.5	109
332	Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H1270-H1285.	1.5	25
333	New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part II. Circulation, 2002, 105, 1503-1508.	1.6	696
334	Cardiac-Specific Expression and Hypertrophic Upregulation of the Feline Na + -Ca 2+ Exchanger Gene H1-Promoter in a Transgenic Mouse Model. Circulation Research, 2002, 90, 158-164.	2.0	32
335	Constitutive properties of hypertrophied myocardium: cellular contribution to changes in myocardial stiffness. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H2173-H2182.	1.5	28
336	Structural components of cardiomyocyte remodeling: Summation. Journal of Cardiac Failure, 2002, 8, S311-S313.	0.7	2
337	New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I. Circulation, 2002, 105, 1387-1393.	1.6	1,078
338	Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H2324-H2335.	1.5	57
339	Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. Journal of the American College of Cardiology, 2001, 37, 1080-1084.	1.2	66
340	Heart Failure With a Normal Ejection Fraction. Circulation, 2001, 104, 779-782.	1.6	437
341	Assessment of Left Ventricular Diastolic Function in Mice. Developments in Cardiovascular Medicine, 2001, , 223-236.	0.1	0
342	Quantification of Diastolic Viscoelastic Properties of Isolated Cardiac Muscle Cells. , 2001, , .		0

#	ARTICLE	IF	CITATIONS
343	Diastolic heart failure: Diagnosis and treatment. <i>Clinical Cornerstone</i> , 2000, 3, 13-24.	1.0	11
344	Diastolic heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2000, 2, 439-450.	0.4	14
345	Integrin Activation and Focal Complex Formation in Cardiac Hypertrophy. <i>Journal of Biological Chemistry</i> , 2000, 275, 35624-35630.	1.6	118
346	Microtubule Depolymerization Normalizes In Vivo Myocardial Contractile Function in Dogs With Pressure-Overload Left Ventricular Hypertrophy. <i>Circulation</i> , 2000, 102, 1045-1052.	1.6	71
347	Effects of Gene Deletion of the Tissue Inhibitor of the Matrix Metalloproteinase-type 1 (TIMP-1) on Left Ventricular Geometry and Function in Mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 109-120.	0.9	115
348	Role of microtubules in the contractile dysfunction of hypertrophied myocardium. <i>Journal of the American College of Cardiology</i> , 1999, 33, 250-260.	1.2	62
349	Matrix Metalloproteinase Inhibition During the Development of Congestive Heart Failure. <i>Circulation Research</i> , 1999, 85, 364-376.	2.0	319
350	Constitutive Properties of Adult Mammalian Cardiac Muscle Cells. <i>Circulation</i> , 1998, 98, 567-579.	1.6	52
351	Cytoskeletal Role in the Transition From Compensated to Decompensated Hypertrophy During Adult Canine Left Ventricular Pressure Overloading. <i>Circulation Research</i> , 1998, 82, 751-761.	2.0	117
352	Mechanisms of cardiac hypertrophy in canine volume overload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H65-H74.	1.5	24
353	Premorbid Determinants of Left Ventricular Dysfunction in a Novel Model of Gradually Induced Pressure Overload in the Adult Canine. <i>Circulation</i> , 1997, 95, 1601-1610.	1.6	65
354	Cytoskeletal Mechanics in Pressure-Overload Cardiac Hypertrophy. <i>Circulation Research</i> , 1997, 80, 281-289.	2.0	147
355	Effect of catheter positioning on the variability of measured gradient in aortic stenosis. <i>Catheterization and Cardiovascular Diagnosis</i> , 1993, 30, 287-292.	0.7	31
356	Left ventricular hypertrophy in a canine model of reversible pressure overload. <i>Cardiovascular Research</i> , 1992, 26, 580-585.	1.8	13
357	Hemodynamic Determinants of Echocardiographically-Derived Indices of Left Ventricular Filling. <i>Echocardiography</i> , 1992, 9, 289-300.	0.3	13
358	And The Band Played On: Persistent Fibrosis After Unbanding Reveals Sex-Dependent Differences in Rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 0, , .	1.5	0